Trial · NCT06123364
Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder
NCT06123364, Not applicable, Completed, Serdinsek Tamara
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder. Trials, record NCT06123364. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06123364
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder
- NCT number
- NCT06123364
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 56 participants, actual
- Lead sponsor
- Serdinsek Tamara
- Conditions
- Overactive Bladder, Overactive Bladder Syndrome
- Interventions
- mirabegron 50 mg daily, Extracorporeal magnetic innervation (active treatment), Extracorporeal magnetic innervation (sham treatment)
- First posted
- 2023-11-08
- Last updated
- 2023-11-09
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in the rate of urgency incontinence episodes | From enrollment to the end of treatment at 8 weeks | The investigators will monitor the rate of urgency incontinence episodes at the enrollment and throughout the study to detect a possible urgency incontinence rate change. |
| Secondary | Change in Incontinence Quality of Life Questionnaire (I-QOL) Score | From enrollment to the end of treatment at 8 weeks | The investigators will monitor the change in Incontinence Quality of Life Questionnaire (I-QOL) Score at the enrollment and throughout the study to detect a possible improvement in quality of life. The score rage is from values 0 to 100, where higher scores mean a better outcome. |
| Secondary | Change in Incontinence Impact Questionnaire - short form (IIQ-7) Score | From enrollment to the end of treatment at 8 weeks | The investigators will monitor the change in Incontinence Impact Questionnaire - short form (IIQ-7) Score at the enrollment and throughout the study to detect a possible improvement in quality of life. The score rage is from values 0 to 100, where lower scores mean a better outcome. |
| Secondary | Change in Urogenital Distress Inventory - short form (UDI-6) Score | From enrollment to the end of treatment at 8 weeks | The investigators will monitor the change in Urogenital Distress Inventory - short form (UDI-6) Score at the enrollment and throughout the study to detect a possible improvement in quality of life. The score rage is from values 0 to 100, where lower scores mean a better outcome. |
| Secondary | Change in Patient Perception of Intensity of Urgency Scale (PPIUS) | From enrollment to the end of treatment at 8 weeks | The investigators will monitor the change in Patient Perception of Intensity of Urgency Scale (PPIUS) at the enrollment and throughout the study to detect a possible improvement in quality of life. The score rage is from values 0 to 4, where lower scores mean a better outcome. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06123364
GET https://conductscience.org/api/trials/v1/NCT06123364/registered